Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion

Human Gene Therapy

Volumn 12, Issue 13, 2001, Pages 1651-1661

  Bristol, J A ^a   Gallo Penn, A ^a   Andrews, J ^a   Idamakanti, N ^a   Kaleko, M ^a   Connelly, S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; CD4 ANTIGEN; CD8 ANTIGEN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEMOPHILIA A; IMMUNIZATION; LIVER; MOUSE; NONHUMAN; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; VIRUS GENE; VIRUS STRAIN;

ADENOVIRIDAE; ALBUMINS; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; FACTOR VIII; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN ISOTYPES; LIVER; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; OVALBUMIN; PROMOTER REGIONS (GENETICS); T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 0034814009     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340152528147     Document Type: Article

References (56)

1. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
2. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
3. German recommendations for immune tolerance therapy in typical haemophiliacs with antibodies
4. In vivo dose threshold effect of adeno-virus-mediated factor VIII gene therapy in hemophiliac mice
5. The canine factor VIII cDNA and 5 flanking sequence
6. Induction of tolerance to human factor VIII in mice
7. Sustained expression of human factor VIII in mice using a parvovirus-based vector
8. Gene therapy for hemophilia
9. Haemophilia A gene therapy
10. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice
11. Sustained expression of therapeutic levels of human factor VIII in mice
12. Complete short-term correction of canine hemophilia A by in vivo gene therapy
13. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
14. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice
15. Sequence of the murine factor VIII cDNA
16. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice
17. Tolerance induction using the Malmo treatment model 1982-1995
18. In vivo evaluation of an adenoviral vector encoding canine factor VIII: High-level, sustained expression in hemophiliac mice
19. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs
20. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy
21. Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3
22. + inflammatory T cell clones in short-term assay
23. The cDNA and derived amino acid sequence of porcine factor VIII
24. Clotting factor concentrates and immune function in haemophilic patients
25. Characterization of dysfunctional factor VIII molecules
26. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig
27. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
28. The immunological characterization of human antibodies to factor VIII isolated by affinity chromatography
29. Gene therapy for the hemophilias
30. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver
31. An introduction to factor VIII inhibitors: The detection and quantitation
32. Development of high-capacity adenoviral vectors for gene therapy
33. Molecular diagnosis of inherited bleeding disorders thrombophilia
34. Gene therapy for hemophilia A and B: Patient selection and follow-up, requirements for a cure
35. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
36. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
37. An ade-noviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
38. Induction of immune tolerance in haemophilia A inhibitor patients by the "Bonn Protocol": Predictive parameter for therapy duration and outcome
39. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver
40. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors
41. The molecular basis of haemophilia A
42. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A
43. Prevention and treatment of factor VIII inhibitors in murine hemo-philia A
44. Characterization of antibodies induced by human factor VIII in a mouse knockout model of hemophilia A
45. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII
46. The natural history of the immune response to exogenous factor VIII in severe haemophilia A
47. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway
48. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector
49. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: Comprehensive analysis of experience at a single institution
50. Molecular cloning of a cDNA encoding human antihaemophilic factor
51. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable forin vitro pro-coagulant activity
52. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice
53. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD41 CTLsin vivo
54. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
55. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs
56. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytesin vivo